论文部分内容阅读
目的 评价以吡柔比星(THP)+环磷酰胺(CTX)+顺铂(DDP)治疗转移性乳腺癌的疗效和毒性,探讨进一步提高THP剂量强度的可能性。方法 自1994年6月到1997年2月,我们以THP(30mg/m~2)iv d_1、d_2+CTX(600mg/m~2)iv d_1+DDP(30mg/m~2)iv d_1～d_3治疗了24例有可测量或评价指标的转移性乳腺癌。结果 有效率69.6％,完全缓解(CR)17.4％,部分缓解(PR)52.2％,稳定(NC)21.7％,进展(PD)8.7％,中位缓解期9月(2～27),中位生存期(2～35)。毒付反应:白细胞下降Ⅲ～Ⅳ度34.7％,恶心、呕吐Ⅲ度8.7％。结论 THP+CTX+DDP治疗转移性乳腺癌活性较高,毒性可耐受,在集落刺激因子的支持下可进一步提高THP的剂量强度。
Objective To evaluate the efficacy and toxicity of pirarubicin (THP) + cyclophosphamide (CTX) + cisplatin (DDP) in the treatment of metastatic breast cancer, and to explore the possibility of further increasing the dose intensity of THP. Methods From June 1994 to February 1997, we used iv d_1 (30 mg/m~2), d_2+CTX (600 mg/m~2) iv d_1, and DDP (30 mg/m~2) iv d_1 to d_3. Twenty-four patients with metastatic breast cancer with measurable or assessed indicators were treated. Results The effective rate was 69.6%, complete remission (CR) was 17.4%, partial remission (PR) was 52.2%, stable (NC) was 21.7%, progression (PD) was 8.7%, median remission was September (2-27), median Lifetime (2 to 35). Toxicological response: Leucocytes decreased by III-IV 34.7%, nausea, vomiting III-degree 8.7%. Conclusion THP+CTX+DDP is effective in treating metastatic breast cancer, and its toxicity can be tolerated. With the support of colony stimulating factor, the dose intensity of THP can be further increased.